Publications by authors named "Ana L Perdigoto"

Claim this Profile
C
CTLA-4 blockade shifts the B cell repertoire toward autoimmunity.
Elif Çakan, Meng Wang, Yile Dai, Adrien Mirouse, Clarence Rachel Villanueva-Pachas, Ana Luisa Perdigoto

J Clin Invest· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune checkpoint inhibitor-induced diabetes can potentially be effectively treated with infliximab: a case report of two patients.
Noam Savion Gaiger, Michael E Hurwitz, Navid Hafez, Harriet M Kluger, Kevan C Herold, Ana Luisa Perdigoto

Front Endocrinol (Lausanne)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Towards insulin independence in type 1 diabetes: Prospects for prevention and cure.
Guy I Sydney, Ana Luisa Perdigoto, Kevan C Herold

PLoS Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors.
Ling Zhu, Yee-Ming M Cheung, Cherie Chiang, Emily J Gallagher, Ole-Petter R Hamnvik, Ana Luisa Perdigoto

J Immunother Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes.
Lilach Aizenbud, Noam Savion Gaiger, Ana Luisa Perdigoto, Jacqueline E Mann, Madeline Candelas Torres

J Immunother Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autoimmune origin for immune checkpoint inhibitor-diabetes revealed by deep immune phenotyping of the pancreas.
Zoe Quandt, Arabella Young, Graham Larson Barlow, Jennifer A Smith, Irina Kusmartseva, Ana Luisa Perdigoto

J Immunother Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The immunology of type 1 diabetes.
Kevan C Herold, Thomas Delong, Ana Luisa Perdigoto, Noah Biru, Todd M Brusko

Nat Rev Immunol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better.
Dijana Djureinovic, Sarah A Weiss, Irina Krykbaeva, Rihao Qu, Ioannis Vathiotis, Ana L Perdigoto

Mol Cancer· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to " germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng.
Lilach Aizenbud, David A Schoenfeld, Jasmine I Caulfield, Jacqueline E Mann, Matthew R Austin, Ana Luisa Perdigoto

J Immunother Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors.
Jasmine I Caulfield, Lilach Aizenbud, Ana Luisa Perdigoto, Eric Meffre, Lucia Jilaveanu

J Immunother Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor-Induced Hypophysitis.
Zoe Quandt, Stephanie Kim, Javier Villanueva-Meyer, Catherine Coupe, Arabella Young, Ana Luisa Perdigoto

J Endocr Soc· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor-induced diabetes.
Ana Luisa Perdigoto, Songyan Deng, Katherine C Du, Manik Kuchroo, Daniel B Burkhardt

JCI Insight· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Citrullination of glucokinase is linked to autoimmune diabetes.
Mei-Ling Yang, Sheryl Horstman, Renelle Gee, Perrin Guyer, TuKiet T Lam, Ana L Perdigoto

Nat Commun· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function.
Shlomit Jessel, Sarah A Weiss, Matthew Austin, Amit Mahajan, Katrina Etts, Ana Luisa Perdigoto

Front Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tet2 Controls the Responses of β cells to Inflammation in Autoimmune Diabetes.
Jinxiu Rui, Songyan Deng, Ana Luisa Perdigoto, Gerald Ponath, Romy Kursawe

Nat Commun· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantifying the effect of experimental perturbations at single-cell resolution.
Daniel B Burkhardt, Jay S Stanley, Alexander Tong, Ana Luisa Perdigoto, Scott A Gigante

Nat Biotechnol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adverse events induced by immune checkpoint inhibitors.
Ana Luisa Perdigoto, Harriet Kluger, Kevan C Herold

Curr Opin Immunol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors.
Zoe Quandt, Arabella Young, Ana Luisa Perdigoto, Kevan C Herold, Mark S Anderson

Annu Rev Med· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elective Colectomy in a Patient with Active Ulcerative Colitis and Metastatic Melanoma Enabling Successful Treatment with Immune Checkpoint Inhibitors.
Ana Luisa Perdigoto, Thuy Tran, Natalie Patel, Pamela Clark, Kanchi Patell

Clin Oncol Case Rep· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Î
β cell responses to inflammation.
Sahar Usmani-Brown, Ana Luisa Perdigoto, Nathalie Lavoie, Pamela Clark, Maria Korah

Mol Metab· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome.
Ana Luisa Perdigoto, Zoe Quandt, Mark Anderson, Kevan C Herold

Lancet Diabetes Endocrinol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.
Ana Luisa Perdigoto, Paula Preston-Hurlburt, Pamela Clark, S Alice Long, Peter S Linsley

Diabetologia· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and Analysis of Islet Antigen-Specific CD8 T Cells with T Cell Libraries.
Hideki Ogura, Paula Preston-Hurlburt, Ana Luisa Perdigoto, Matthew Amodio, Smita Krishnaswamy

J Immunol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.
Angeliki M Stamatouli, Zoe Quandt, Ana Luisa Perdigoto, Pamela L Clark, Harriet Kluger

Diabetes· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Have we pushed the needle for treatment of Type 1 diabetes?
Nida Naushad, Ana Luisa Perdigoto, Jinxiu Rui, Kevan C Herold

Curr Opin Immunol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis